GRB7 Activators
The regulation of Growth Factor Receptor-Bound Protein 7 (GRB7) involves a diverse array of chemical modulators that intricately influence its activity, connecting cellular signaling pathways to essential cellular processes. While direct activators specifically targeting GRB7 are not yet identified, indirect modulation through interconnected pathways reveals a complex regulatory landscape. Inhibitors of key signaling molecules, such as SH-4-54 and BMS-754807, showcase indirect modulation of GRB7 through the inhibition of STAT3 and IGF-1R, respectively. By disrupting downstream signaling pathways associated with these molecules, these compounds potentially activate GRB7 by altering the transcriptional regulation of genes connected to growth factor receptor signaling pathways. NSC 23766 and JAK Inhibitor I exemplify indirect modulators of GRB7 through the inhibition of Rho GTPase Rac1 and JAKs, respectively. These compounds can potentially activate GRB7 by influencing cellular processes regulated by Rac1 and JAK-STAT signaling, thereby impacting the downstream pathways associated with GRB7 function.
Compounds like PD 0325901 and Ruxolitinib indirectly influence GRB7 by inhibiting MEK1/2 and JAK1/2, respectively. By disrupting the MAPK/ERK and JAK-STAT signaling pathways, these compounds potentially activate GRB7 by altering downstream signaling cascades connected to growth factor receptor activation and the regulatory role of GRB7. Inhibitors such as Y-27632 and SU6656 impact GRB7 indirectly through the modulation of ROCK and Src family kinases, respectively. These compounds can potentially activate GRB7 by influencing the actin cytoskeleton dynamics and downstream signaling pathways associated with Src family kinase-mediated regulation of GRB7. The p38 MAP kinase inhibitor Doramapimod and FLT3 inhibitor UNC-21453 showcase indirect modulation of GRB7 by influencing p38 MAP kinase and FLT3 signaling, respectively. These compounds potentially activate GRB7 by disrupting downstream signaling cascades associated with growth factor receptor activation and the regulatory role of GRB7.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807 is a potent and selective inhibitor of insulin-like growth factor 1 receptor (IGF-1R). Its indirect modulation of GRB7 involves inhibiting IGF-1R, potentially activating GRB7 by disrupting downstream signaling pathways associated with IGF-1R and its interaction with GRB7. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
JAK Inhibitor I inhibits Janus kinases (JAKs). Its indirect modulation of GRB7 involves dampening JAK-STAT signaling, potentially activating GRB7 by altering the transcriptional regulation of genes associated with growth factor receptor pathways that intersect with GRB7 function. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib inhibits JAK1 and JAK2. Its indirect modulation of GRB7 involves suppressing JAK-STAT signaling, potentially activating GRB7 by altering the transcriptional regulation of genes associated with growth factor receptor pathways that intersect with GRB7 function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). Its indirect influence on GRB7 involves modulating ROCK-mediated signaling, potentially activating GRB7 by influencing the actin cytoskeleton dynamics and cellular processes connected to ROCK and GRB7 functions. | ||||||
SU6656 | 330161-87-0 | sc-203286 sc-203286A | 1 mg 5 mg | $57.00 $133.00 | 27 | |
SU6656 is a Src family kinase inhibitor. Its indirect modulation of GRB7 involves inhibiting Src family kinases, potentially activating GRB7 by disrupting downstream signaling pathways associated with growth factor receptor activation and Src family kinase-mediated regulation of GRB7. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Doramapimod is a selective p38 MAP kinase inhibitor. Its indirect impact on GRB7 involves inhibiting p38 MAP kinase signaling, potentially activating GRB7 by influencing downstream signaling cascades associated with growth factor receptor activation and the regulatory role of GRB7. | ||||||
BMS 777607 | 1025720-94-8 | sc-364438 sc-364438A | 10 mg 50 mg | $400.00 $1269.00 | 1 | |
BMS-777607 is a selective inhibitor of MET and VEGFR2. Its indirect impact on GRB7 involves inhibiting MET, potentially activating GRB7 by disrupting downstream signaling pathways associated with MET and the regulatory role of GRB7 in coordinating cellular responses to growth factor signals. | ||||||